PMEL17 ANTIBODIES AND CONJUGATES BASED THEREON Russian patent published in 2024 - IPC C07K16/30 C07K16/00 C07K16/18 G01N33/574 A61K39/395 A61K35/00 A61K45/06 A61P35/00 

FIELD: biotechnology.

SUBSTANCE: disclosed are: antibodies or antigen-binding fragments thereof, which bind to human PMEL17 protein, which contain certain amino acid sequences, method for production and use thereof for treating or preventing cancer in a patient in need thereof, conjugates of an antibody and a drug, which bind to a human PMEL17 protein, containing a specific structure, method for their preparation and use for treating or preventing cancer in a patient in need thereof, pharmaceutical compositions for treating or preventing cancer in a patient in need thereof; method of treating or preventing cancer in a patient in need thereof. Also disclosed are: nucleic acid, which codes an antibody or antigen-binding fragment, a host cell for producing an antibody or an antigen-binding fragment, a diagnostic reagent for diagnosing a disease associated with PMEL17 expression.

EFFECT: invention is used to treat cancer, where cancer expresses PMEL17, cancer contains mutation of GNAQ gene and/or GNA11 gene or cancer expresses PMEL17 and contains mutation of GNAQ gene and/or GNA11 gene.

47 cl, 20 dwg, 10 tbl, 2 ex